Goldman Sachs analyst Paul Choi maintained a Buy rating on Gossamer Bio (GOSS – Research Report) today and set a price target of $9.00.
Paul Choi has given his Buy rating due to a combination of factors surrounding Gossamer Bio’s ongoing Phase 3 PROSERA seralutinib trial for pulmonary arterial hypertension (PAH). The anticipation of the topline data, which is expected to be released in the fourth quarter of 2025, is a significant element of the positive outlook. Despite the recent quarter’s financial results being considered a non-event, investor interest remains high in the company’s clinical trial progress and the potential market impact of competitor drugs, such as sotatercept by Merck, pending FDA approval.
Moreover, the inclusion of Japanese clinical sites in the PROSERA trial by the PMDA is seen as a positive development, potentially accelerating patient enrollment and broadening the global implications of the trial results. The focus on the trial’s enrollment pace and the unique characteristics of the study population are key factors that could differentiate Gossamer Bio’s seralutinib from other treatments in PAH. While Choi has lowered the price target slightly, the maintained Buy rating suggests a continued confidence in Gossamer Bio’s value proposition and its prospects in the PAH drug market.
According to TipRanks, Choi is a 4-star analyst with an average return of 9.0% and a 56.90% success rate. Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Ascendis Pharma, and Amarin.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Gossamer Bio (GOSS) Company Description:
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Read More on GOSS:
